Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2

Published:2021-03 Issue: Volume: Page:
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Peele K.Abraham,Kumar Vikas,Parate Shraddha,Srirama Krupanidhi,Lee Keun Woo,Venkateswarulu T.C.

Funder

Ministry of Science and ICT, South Korea

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference82 articles.

1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2;Gorbalenya;Nat Microbiol,2020

2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges;Lai;Int J Antimicrob Agents,2020

3. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N Engl J Med,2020

4. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence;Wang;Int J Antimicrob Agents,2020

5. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries;Grant;PLoS ONE,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates;Pathology - Research and Practice;2024-11

2. New perspective of small-molecule antiviral drugs development for RNA viruses;Virology;2024-06

3. Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules;Applied Biological Chemistry;2023-12-13

4. Implications of antibiotics and antimicrobial resistance development during COVID-19;Genomic Surveillance and Pandemic Preparedness;2023

5. In-silico screening to delineate novel antagonists to SARS-CoV-2 nucleocapsid protein;Physics and Chemistry of the Earth, Parts A/B/C;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3